Effect of PCSK9 Inhibitor on Contrast-Induced Acute Kidney Injury in Patients with Acute Myocardial Infarction Undergoing Intervention Therapy

Table 4

Logistic regression analysis of patients with acute myocardial infarction undergoing coronary intervention (n = 309).

	B	SE	Wald c^2	value	OR	95% CI
Evolocumab	1.62	0.46	12.65	<0.01	5.07	2.07–12.39
Killip class I	−1.26	0.78	2.59	0.11	0.29	0.06–1.31
Hs-CRP	<0.01	0.01	<0.01	0.99	1.00	0.99–1.02
Emergency PCI	0.31	0.44	0.51	0.47	1.37	0.58–3.22
Age >70 years	-0.55	0.42	1.76	0.19	0.58	0.26–1.30
Hypertension	−0.23	0.44	0.28	0.60	0.80	0.34–1.85
LVEF <45%	−0.58	0.42	1.87	0.17	0.56	0.25–1.28
Anemia	−0.09	0.87	0.01	0.92	0.92	0.17–4.99
Diabetes mellitus	−1.09	0.40	7.50	<0.01	0.34	0.15–0.73
Previous MI	0.10	0.48	0.04	0.84	1.10	0.43–2.80
Contrast medium dose >150 mL	−0.44	0.51	0.76	0.39	0.64	0.24–1.74
Iodixanol	−0.13	0.73	0.03	0.86	0.88	0.21–3.70

B, beta; SE, standard error; OR, odds ratio; CI, confidence interval; hs-CRP, high-sensitivity C-reactive protein; PCI, percutaneous coronary intervention; LVEF, left ventricular ejection fraction; MI, myocardial infarction.